BCL2 and neoplasm: As presented in Figure 5A, the combination treatment upregulated more significantly the protein expression of cleaved caspases 3 and cleaved PARP and suppressed the Bcl-2 expression level in tumor samples, compared to each single treatment with paclitaxel or XAV939.